GNOM.L
Global X Genomics & Biotechnology UCITs ETF
GNOM invests in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, biotechnology, and more.
US
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 52.9 M
ASSETS UNDER MGMT
50 bp
EXPENSES
Fund Basics
| Inception date | Nov 02, 2021 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| GUARDANT HEALTH, INC. | 6.1 % |
| ILLUMINA INC | 4.9 % |
| TWIST BIOSCIENCE CORP. | 4.7 % |
| NATERA INC | 4.4 % |
| 10X GENOMICS INC CLASS A | 4.3 % |
| MODERNA, INC. | 4.2 % |
| BIO-TECHNE CORPORATION | 4.1 % |
| VERACYTE INC | 3.9 % |
| VERTEX PHARMACEUTICALS INC | 3.8 % |
| BIOMARIN PHARMACEUTICAL INC | 3.7 % |
Constituent Breakdown
| Number of holdings | 50 |
| Herfindahl-Hirschman Index | 323 |
| Wgt avg mkt cap (mns) | $48,912 |
| Large cap (>$10bn) | 45.7% |
| Mid cap ($2-10bn) | 44.4% |
| Small cap (<$2bn) | 9.9% |
| Developed mkts. | 98.3% |
| Emerging mkts. | 1.8% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 84.2 % |
 |
NETHERLANDS | 5.6 % |
 |
SWITZERLAND | 3.2 % |
 |
GERMANY | 2.8 % |
 |
CHINA | 1.8 % |
 |
BRITAIN | 1.5 % |
 |
SINGAPORE | 0.9 % |
Historical Performance
Standardized Performance (as of 05/31/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 8.0% | 60.5% | 10.2% | 1.2% | -- | -- | -- | -11.5% |
| Dividend Yield | 0.0% | 0.0% | 0.0% | 0.0% | -- | -- | -- | 0.0% |
| Total Returns | 8.0% | 60.5% | 10.2% | 1.2% | -- | -- | -- | -11.5% | Ann. Volatility | 30.6% | 28.5% | 30.2% | 29.7% | -- | -- | -- | 33.1% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.16 | 23% |
| MSCI EAFE | 0.88 | 21% |
| MSCI Emg Mkts | 0.67 | 22% |
Liquidity Measures
| Avg. volume (000) | 14 |
| ADV traded (mns) | $0 |
| Turnover | 0.3% |
| Avg. Bid/Ask (% of price) | 0.00% |
Technical Indicators
| 30d moving avg. (EMA) | $8.25 |
| Relative strength (RSI) | 59 |
| MACD/Signal | 0.12/0.05 |
| Bollinger Bands (Upper/Lower) | $8.74/$7.75 |
| Short interest (% of AUM) | 0.0% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. GNOM.L |
Expenses vs. GNOM.L |
ALTAR Score™ vs. GNOM.L |
|---|---|---|---|---|
| WDNA.L | WisdomTree BioRevolution UCITS ETF - USD Acc | 34.9% | -5 bp | -0.3% |
| XGEN.DE | Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C | 32.3% | -20 bp | +3.0% |
| EDOC.L | Global X Telemedicine & Digital Health UCITS ETF | 18.4% | +18 bp | +3.0% |
| HEAL.L | iShares Healthcare Innovation UCITS ETF | 18.1% | -10 bp | +5.0% |
| BTEC.L | iShares Nasdaq US Biotechnology UCITS ETF | 16.7% | -15 bp | +2.5% |
| BTEE.L | iShares Nasdaq US Biotechnology UCITS ETF | 16.7% | -15 bp | +2.5% |
| XDG3.DE | Xtrackers MSCI Global SDG 3 Good Health UCITS ETF 1C | 13.3% | -15 bp | +8.9% |
| XNNV.DE | Xtrackers MSCI Innovation UCITS ETF 1C | 10.7% | -20 bp | +6.1% |
| XDWH.DE | Xtrackers MSCI World Health Care UCITS ETF 1C | 10.2% | -25 bp | +9.3% |
| WHCA.L | iShares MSCI World Health Care Sector Advanced UCITS ETF | 10.1% | -32 bp | +9.0% |
Risk and Returns: GNOM.L vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 7/15/2026
Peer Group Comparison
Sample data. Subscribe for access.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
-2.7%
ALTAR SCORE™
1st
PERCENTILE
AVOID
ETFRC RATING
There are 1,400 funds in the US Equity category with an average
ALTAR Score™ of 5.4% and a standard deviation
of 2.1%. GNOM.L's ALTAR Score™ is approximately -3.8 standard
deviations above the category average. This places GNOM.L in the 1st percentile
among funds in the category.
Sell-Side Consensus
$11.56
PRICE TARGET
+16.3%
UPSIDE